cardiovascular outcomes glp-1 news today 363. Agonists: Diving into the Data with Dr. Darren McGuire Cardiovascular outcomes in major trials

#Cardiology #ASCVD #ClinicalResearch #CardiovascularRisk #Obesity #EvidenceBasedMedicine #PrecisionMedicine Evolocumab can help attenuate the elevated risk of major adverse cardiovascular events that individuals with obesity and atherosclerotic cardiovascular disease (ASCVD) face, according to a prespecified analysis from the FOURIER trial published in #JACC

doi: 10.1007/s11914-024-00874-2 99 MorrisonSJScaddenDT

Verifying source credentials, understanding product concentration, and discussing potential interactions with existing medications or health conditions should precede any therapeutic use

Greasy and foul-smelling stool may suggest fat malabsorption caused by conditions like celiac disease, pancreatitis, or parasitic infections such as giardiasis